ROCHE HOLDINGS AG (RHHBY)

33.86
0.07 0.21
OTC
Prev Close 33.93
Open 33.81
Day Low/High 33.72 / 33.90
52 Wk Low/High 26.30 / 34.98
Volume 367.73K
Exchange OTC
Shares Outstanding 702.56B
Market Cap 195.59B
Div & Yield N.A. (N.A)
Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Roche Holding AG Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of August 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Roche Holding AG ("Roche Holding") (OTCMKTS: RHHBY) between...

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Roche Holding AG

The Klein Law Firm announces the commencement of an investigation of Roche Holding AG (OTCMKTS: RHHBY) concerning possible violations of federal securities laws.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Roche Holding AG

The Klein Law Firm announces the commencement of an investigation of Roche Holding AG (OTCMKTS: RHHBY) concerning possible violations of federal securities laws.

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Roche Holding AG Investors And Encourages Investors To Contact The Firm

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Roche Holding AG ("Roche" or the "Company") (OTC: RHHBY) securities between March 2, 2017...

RHHBY INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Concerning Possible Securities Violations By Roche Holding AG

The Law Offices of Vincent Wong announce the commencement of an investigation concerning whether Roche Holding AG ("Roche Holding") (OTCMKTS:RHHBY) violated federal securities laws.

RHHBY SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Concerning Possible Securities Violations By Roche Holding AG

The Law Offices of Vincent Wong announce the commencement of an investigation concerning whether Roche Holding AG ("Roche Holding") (OTCMKTS: RHHBY) violated federal securities laws.

ROCHE LOSS NOTICE: Rosen Law Firm Reminds Roche Holding AG Investors Of Important Deadline In First Filed Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Roche Holding AG (OTCQX:RHHBY) from March 2, 2017 through June 5, 2017, inclusive (the "Class Period") of the important August 7,...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Roche Holding AG

Levi & Korsinsky announces it has commenced an investigation of Roche Holding AG (OTCMKTS:RHHBY) concerning possible violations of federal securities laws.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Roche Holding AG

Levi & Korsinsky announces it has commenced an investigation of Roche Holding AG (OTCMKTS:RHHBY) concerning possible violations of federal securities laws.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

INVESTOR ALERT: Goldberg Law PC Announces The Filing Of A Securities Class Action Lawsuit Against Roche Holding AG

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Roche Holding AG ("Roche" or the "Company") (Other OTC: RHHBY) for violations of §§10(b) and...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Roche Holding AG - RHHBY

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Roche Holding AG (OTCQX: RHHBY) from March 2, 2017 through June 5, 2017,...

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Roche Holding AG Investors

Glancy Prongay & Murray LLP ("GPM") is investigating potential claims on behalf of investors of Roche Holding AG ("Roche" or the "Company") (Other OTC: RHHBY) concerning the Company and its officers'...

Here's Why There Is a Sea of Red Across Global Stock Markets Tuesday

Here's Why There Is a Sea of Red Across Global Stock Markets Tuesday

European stocks fell firmly amid a global equity market pullback.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures decline and shares in Europe fall amid a weak U.S. dollar, rising political tensions in the Gulf region and electoral risks in the U.K.

Roche Plunges After a Key Breast Cancer Treatment Trial Disappoints

Roche Plunges After a Key Breast Cancer Treatment Trial Disappoints

Not a good session for Roche.

Global Investors Adjust to Rising Political Risks

Global Investors Adjust to Rising Political Risks

European stocks open lower Tuesday as global investors trim risky positions amid rising political tensions in the Gulf region and the ongoing turmoil in the White House.

COMPANY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Roche Holding AG To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Roche Holding AG ("Roche" or the "Company") (OTCQX:RHHBY).

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Roche Holding AG - RHHBY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Roche Holding AG.

APHINITY Study Shows Genentech's Perjeta-Based Regimen Reduced The Risk Of Invasive Cancer Returning Compared To Herceptin And Chemotherapy In HER2-Positive Early Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III...

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.

Phase III Study Showed Genentech's Alecensa (Alectinib) Reduced The Risk Of Disease Progression Or Death By More Than Half Versus Crizotinib As First-Line Treatment In A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III ALEX study showed Alecensa ® (alectinib) significantly reduced the risk of disease worsening or death...

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.

FDA Approves Genentech's Actemra (Tocilizumab) For Giant Cell Arteritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.

Genentech To Present New Data On Personalized Medicines And Cancer Immunotherapies At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual...

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?